Nektar Therapeutics (LON:0UNL)

Nektar Therapeutics Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	633	137	85	353	1,841	2,234
Market Cap Growth	335.60%	61.93%	-76.00%	-80.86%	-17.57%	-22.09%
Enterprise Value	556	103	-16	148	1,378	1,550
Last Close Price	31.10	10.98	6.64	27.51	151.88	184.73
PS Ratio	13.58	1.74	1.20	4.61	24.47	19.94
PB Ratio	9.99	2.82	0.82	1.16	3.67	2.83
P/TBV Ratio	9.99	2.82	0.82	1.46	4.14	3.05
EV/Sales Ratio	11.97	1.31	-	1.94	18.31	13.84
EV/FCF Ratio	-3.93	-	-	-	-	-
Debt / Equity Ratio	1.96	3.20	1.76	0.78	0.50	0.33
Asset Turnover	0.21	0.28	0.16	0.10	0.08	0.09
Inventory Turnover	-	-	1.91	1.24	1.60	1.39
Quick Ratio	4.09	4.18	5.97	7.53	8.90	9.55
Current Ratio	4.24	4.26	6.45	8.01	9.34	9.83
Return on Equity (ROE)	-180.24%	-124.10%	-110.95%	-70.39%	-59.64%	-35.80%
Return on Assets (ROA)	-27.98%	-23.14%	-15.25%	-16.43%	-21.00%	-13.51%
Return on Capital (ROIC)	-33.61%	-26.34%	-16.66%	-17.96%	-22.80%	-14.33%
Return on Capital Employed (ROCE)	-58.00%	-53.60%	-39.00%	-37.40%	-43.20%	-26.70%
Earnings Yield	-14.20%	-69.35%	-256.12%	-86.68%	-21.01%	-14.57%
FCF Yield	-22.39%	-103.28%	-179.50%	-72.91%	-17.15%	-10.51%
Buyback Yield / Dilution	-14.07%	-8.24%	-1.53%	-2.10%	-2.64%	-2.05%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.